TransMontaigne (TLP) Receives News Sentiment Rating of 0.09

Media headlines about TransMontaigne (NYSE:TLP) have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. TransMontaigne earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news stories about the pipeline company an impact score of 47.0363847008292 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Several research firms have commented on TLP. Zacks Investment Research downgraded shares of TransMontaigne from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. B. Riley set a $45.00 price objective on shares of TransMontaigne and gave the company a “neutral” rating in a report on Monday, December 18th. Stifel Nicolaus upped their price objective on shares of TransMontaigne from $42.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, March 20th. Finally, UBS reiterated a “buy” rating and issued a $59.00 price objective (up from $53.00) on shares of TransMontaigne in a report on Friday, March 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $49.17.

How to Become a New Pot Stock Millionaire

Shares of TLP stock traded down $0.54 on Friday, hitting $36.27. The company’s stock had a trading volume of 21,630 shares, compared to its average volume of 45,048. The company has a debt-to-equity ratio of 1.63, a quick ratio of 1.31 and a current ratio of 1.31. TransMontaigne has a fifty-two week low of $33.97 and a fifty-two week high of $47.45. The company has a market capitalization of $595.49, a PE ratio of 16.49, a price-to-earnings-growth ratio of 2.47 and a beta of 0.19.

TransMontaigne (NYSE:TLP) last released its quarterly earnings results on Thursday, March 15th. The pipeline company reported $0.41 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.52 by ($0.11). TransMontaigne had a net margin of 24.56% and a return on equity of 12.16%. The business had revenue of $47.61 million during the quarter, compared to analyst estimates of $45.09 million. analysts forecast that TransMontaigne will post 2.49 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3338388/transmontaigne-tlp-receives-news-sentiment-rating-of-0-09.html.

About TransMontaigne

TransMontaigne Partners L.P. provides integrated terminaling, storage, transportation, and related services. The company offers its services to customers engaged in the trading, distribution, and marketing of light and heavy refined petroleum products, crude oil, chemicals, fertilizers, and other liquid products.

Insider Buying and Selling by Quarter for TransMontaigne (NYSE:TLP)

Receive News & Ratings for TransMontaigne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMontaigne and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Motorcar Parts of America  Stock Rating Lowered by BidaskClub
Motorcar Parts of America Stock Rating Lowered by BidaskClub
Lennar Co.  Announces $0.04 Quarterly Dividend
Lennar Co. Announces $0.04 Quarterly Dividend
Q2  Reaches New 12-Month High and Low at $48.92
Q2 Reaches New 12-Month High and Low at $48.92
Momenta Pharmaceuticals  Hits New 1-Year High and Low at $20.35
Momenta Pharmaceuticals Hits New 1-Year High and Low at $20.35
Abiomed  Reaches New 12-Month High and Low at $305.63
Abiomed Reaches New 12-Month High and Low at $305.63
CEVA  Rating Increased to Hold at BidaskClub
CEVA Rating Increased to Hold at BidaskClub


Leave a Reply

© 2006-2018 Ticker Report. Google+.